| Protocol |
Title |
Status |
Contact |
| 104197 |
NRG-GU013: THE PHASE III HIGH FIVE TRIAL FIVE FRACTION RADIATION FOR HIGH-RISK PROSTATE CANCER |
OPEN TO ACCRUAL |
 |
| 103876 |
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3) |
OPEN TO ACCRUAL |
|
| 104037 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease. |
OPEN TO ACCRUAL |
|
| 104171 |
Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer- Prospect Lung |
OPEN TO ACCRUAL |
|
| 104020 |
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
OPEN TO ACCRUAL |
|
| 104139 |
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy |
OPEN TO ACCRUAL |
|
| 104093 |
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) |
OPEN TO ACCRUAL |
|
| 104078 |
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy |
OPEN TO ACCRUAL |
|
| 104192 |
A012301: LoTam: A Randomized, Phase III Clinical Trial of LowDose Tamoxifen for Selected Patients with Molecular Low-risk EarlyStage Breast Cancer |
OPEN TO ACCRUAL |
|
| 104173 |
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
| 103909 |
A Phase II study of Fingolimod in Patients with Non-Small Cell and Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 104015 |
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
OPEN TO ACCRUAL |
|
| 104144 |
A Phase 1, Open-Label, Multicenter Study of Janx007 in Subjects with Metastatic Castration-Resistant Prostate Cancer |
OPEN TO ACCRUAL |
|
| 104063 |
KRT-232-115: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV MF), or Post Essential Thrombocythemia (post ET MF) That Have a Suboptimal Response to Ruxolitinib |
OPEN TO ACCRUAL |
|
| 104120 |
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for low Tumor Burden Follicular Lymphoma |
OPEN TO ACCRUAL |
|
| 103960 |
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Patients With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
| 104176 |
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma |
OPEN TO ACCRUAL |
|
| 104131 |
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma: a Single Institution Phase II Trial |
OPEN TO ACCRUAL |
|
| 103991 |
M22-574: Phase 3 ABBV-383 vs Standard Available Treatment in Subjects with RRMM with at Least 2 Prior Lines of Therapies |
OPEN TO ACCRUAL |
|
| 104108 |
Phase 3 Study of Bomedemstat vs Best Available Therapy for 2L Essential Thrombocythemia |
OPEN TO ACCRUAL |
|